Archive: Rare Disease

When it comes to recruiting patients for clinical trials in rare diseases, HCP outreach and support is essential. Most trials in the rare disease space struggle with patient recruitment unless they have a well thought out strategy on how to include HCPs in the recruitment process. 

In February 2022, SubjectWell announced the expansion of its proven marketplace to include oncology clinical trials, beginning with non-small cell lung cancer (NSCLC). Lung cancer is by far the leading cause of cancer death, and more specifically, the vast majority of lung cancer diagnoses are NSCLC. To develop a better understanding of NSCLC patients’ attitudes

SubjectWell has been providing risk-free patient recruitment for 10 years, building awareness of the benefits of clinical research and offering choice to patients with chronic ambulatory health conditions by screening for multiple studies at once. And now we’re taking our marketplace one step further. In February 2022, SubjectWell expanded our proven clinical trial marketplace to

Rare disease clinical trials come with a unique set of challenges. However, there are a few strategies that sponsors and CROs can use to boost patient recruitment and retention.

Meeting recruitment goals is incredibly challenging for any clinical trial, but it’s even more so when fewer than 200,000 people nationwide are potential candidates, as is often the case for rare disease studies.

If rare disease clinical trials want to recruit patients more effectively, they need to embrace innovative digital technologies.

With clinical trial costs on the rise and participant recruitment and retention at an all-time low, it’s time for trial recruiters to embrace new solutions.

Recruiting patients with rare and terminal conditions presents a major challenge for CROs and patient coordinators – but digital marketing techniques can help.